Clinical Trials Browser

Phase 1 × INDUSTRY × pelcitoclax × Clear all

NCT04001777 2025-10-01

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Phase 1 Active not recruiting

EGFR Positive Non-small Cell Lung Cancer

NCT04893759 2025-04-17

A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

Phase 1 Terminated

Neuroendocrine Tumors

NCT03387332 2021-08-27

APG-1252 in Patients With SCLC or Advanced Solid Tumors

Phase 1 Terminated

Small Cell Lung Carcinoma